POWERED BY

From Brussels with healthcare. Tilly Metz wants health higher on the EU’s agenda

PublishedNovember 19, 2026

On 12 November 2026, Luxembourg MEP Tilly Metz (Greens/EFA) was elected Vice-President of the European Parliament, taking a seat in the Bureau that oversees how this institution runs.

A few days after her election, she spoke to NXTin.Health about the need to identify vulnerabilities in our supply chains, strengthen Europe’s manufacturing capacity, and the importance of breaking the glass ceiling – a barrier her election has already shattered.

With Roberta Metsola of Malta as President and you now joining the Bureau from Luxembourg, two of the EU’s smallest member states hold senior positions in the European Parliament. Does coming from a small country make a difference?

I always say that small countries are in a better position to build bridges between the big ones. We are often forced to speak several languages, and I see that with Roberta Metsola as well. It helps to build those bridges. Luxembourg is also one of the founding countries of the European Union, and we are very much pro-European. I think all of this helped my candidacy too.

Health has been central to your work as an MEP. What are your priorities now?

I will, of course, continue to work on the European Health Union. It is something very close to my heart. I want to keep working on public health and to put real effort into prevention, equal access to healthcare and the resilience of our healthcare systems.

We have seen in recent years that health challenges rarely stop at national borders. Cancer, infectious diseases, medicine shortages, antimicrobial resistance, the impact of climate change on public health: all of these show that what we really need is European cooperation and European action. At the level of the European Parliament, I will help to put those topics on the agenda.

Does that commitment extend to how the European Parliament itself operates?

Yes, it starts with the people who work in this house. For example, we should use toxic-free cleaning products for the carpets. It is the air we breathe. So it is also about creating a healthy working environment for everyone in the Parliament.

More generally, it is very important to me that our institution stays close to the concerns of citizens. When you look at the Eurobarometer, health is always mentioned. We should take seriously what citizens are asking of us.

You have called for a Europe that is better prepared and more resilient. When it comes to medicine shortages, how do we move from reacting to preventing them?

I think we have taken a serious step with the Critical Medicines Act. The COVID crisis and the shortages of essential medicines that followed such as Ventolin and paracetamol for children, showed how vulnerable European supply chains are. Above all, they showed how quickly a disruption in any part of the world reaches patients here in Europe, because so many active ingredients are made outside the European Union.

So first, we have to identify the vulnerable points in our supply chains. Then we have to strengthen manufacturing capacity in Europe. That is where the Critical Medicines Act can contribute, especially for critical medicines and active pharmaceutical ingredients, where we definitely need more European independence. For that, we need better cooperation between member states, more transparency on supply chains and the risks, and mechanisms to anticipate shortages before they affect patients.

Cooperation between member states is often called for. What is still missing?

Trust. I speak about cooperation, but it goes beyond that. We need more trust among member states, and that is something we really have to work on so that there is a genuine solidarity mechanism between countries when there is a shortage of a medicine.

When we think about what we could have done better in a situation like COVID-19, preparedness is the answer. Better cooperation, trust, planning and anticipation, and a clear commitment at European level that public health is at the centre of our decisions.

Boosting manufacturing also means innovating, which is part of how Europe gains sovereignty. Is Europe doing enough to support innovation? Many innovators say that a CE mark for a medical device is only the beginning, because they then face 27 different adoption and reimbursement systems.

Smiling woman in a green jacket forms a heart shape with her hands as people applaud around her

You have already mentioned some of the barriers we encounter. But in research, there is another crucial question: whose needs and whose experiences are represented in the research we fund? I think we need better coordination by public authorities here.

For too long, women have been underrepresented in medical research, and important gender differences have not always been adequately considered. This is particularly evident in clinical trials. Women’s participation is essential to understanding how treatments work, and how safe and effective they are across different populations. Women are at least 50 per cent of the population. So we need to make sure gender is properly integrated into research priorities, into funding criteria and into clinical trial design.

It also means supporting more women in research careers, addressing the barriers they face and creating opportunities for women-led research teams. If we want research to deliver better innovation, it has to reflect the diversity of our society, so that it addresses the needs of everyone.

We recently interviewed the founder of WiLD Norway, who pointed out that even the Nordic countries, often seen as leaders on equality, still have a large gender gap in life science leadership and investment. Are stricter rules needed?

That is still the reality in 2026, and it is something we need to address.

I think we need clearer rules. When funding is awarded, better representation of women in clinical trials should be part of the criteria. We also need to ask for disaggregated data, so that we have more information on the impact treatments have on women. And yes, we need to enforce it. Otherwise, it may happen with time, because there is also a commercial interest in it. But to be fair, and if we want more personalised medicine that brings real added value for women as well, we need to enforce it.

Has the situation improved?

I think it is better than in the past, but we are still not where we want to be.

Forecasts suggest that around one in two people in the EU will be diagnosed with cancer during their lifetime. A great deal is happening in cancer innovation, but what needs to change for those breakthroughs to reach patients? Can regulation help?

Scientific progress is clearly moving quickly. We are seeing very promising developments in early detection, for instance through AI supporting screening and radiology, and in the direction of personalised medicine. But innovation only makes a real difference when patients can actually benefit from it.

In Europe, we still have huge differences between member states in access to innovative treatments and clinical trials. So we need stronger cooperation, better use of the health data we have, and more effective pathways to bring research into clinical practice.

How does Europe compare with the United States in this regard?

I must say it is a bit easier in the United States. They have a much more integrated market and a different financing environment, which makes it easier for companies to scale up. In Europe, we have excellent research institutions, great scientific talent and very innovative companies. But, as you mentioned, our fragmented markets, fragmented regulatory conditions across member states and different reimbursement systems make that expansion much more difficult.

The challenge today is to build on Europe’s strengths while improving cross-border cooperation, so that access to innovation does not depend on which part of Europe a patient lives in. In the EU, we should ultimately measure progress not simply by what science can achieve, but by how many people can actually benefit from it. If only an elite benefits in the end, the value is limited. We need more harmonisation at European level, so that companies can also scale up their production.

Innovators often say the EU is not one market but 27. Is it realistic to expect that to change, or does the current system have its benefits?

Since you are asking me: I dream of a federal Europe. That is the future for me, although it will still take some time to get there. We clearly have to move towards more harmonisation.

The European Health Data Space is one example. Step by step, it will bring us more harmonisation in how we define diseases, in reimbursement systems and so on. And I come back to trust. Companies and citizens need to know that sharing their data is in their interest, that it can save lives, including when they are abroad. Step by step, that brings us closer to a real Health Union. But it is not for tomorrow. I hope I will still be around when it happens.

You clearly place a lot of hope in the European Health Data Space. Why?

Yes, that is true. I think it can help first and foremost in primary healthcare. But it can also do a lot to make us stronger in research. The European Health Data Space has two levels, and one covers data used for research. If we work together more closely at European level there, we will also get a better analysis of what we need in research at European level. We need a more centralised approach to research priorities, and all of this would come together.

Finally, how do you keep a healthy balance alongside such a demanding schedule?

I started today with sport. I went running and did my Tabata exercises with weights. At least once a week I do meditation, or a kind of meditation, going out into nature with my dogs. Sport, meditation, my dogs and, of course, my family: all of that gives me the resources and the time to disconnect. I also try to take care of what I eat a little. I think that is an important part of it, too.

Picture: https://www.linkedin.com/feed/update/urn:li:activity:7526946297690456064/